AstraZeneca announced the global withdrawal of its Covid-19 vaccine, Vaxzevria, on May 7, 2024, after over three billion doses were administered.

The withdrawal was prompted by the identification of rare but severe side effects, such as blood clots and low platelet counts, and the inefficacy against new virus variants.

A class-action lawsuit has been initiated against AstraZeneca, highlighting claims of death and serious injury connected to the vaccine.

The UK government has committed to covering AstraZeneca's legal costs related to the lawsuit.

Court documents reveal AstraZeneca's admission that its vaccine may cause Thrombosis with Thrombocytopenia Syndrome (TTS).

Criticism has been directed at the UK government and AstraZeneca for their failure to adequately address the vaccine's harmful effects.

Despite Vaxzevria's withdrawal, medical experts maintain that vaccination remains a key strategy in the fight against the COVID-19 pandemic.